Extension Study Evaluating Etanercept in Ankylosing Spondylitis

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00410046
First received: December 8, 2006
Last updated: April 9, 2012
Last verified: April 2012

December 8, 2006
April 9, 2012
December 2006
October 2008   (final data collection date for primary outcome measure)
  • Number of Patients Using Healthcare Resources in the 48 Weeks Before and During Treatment [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
    Healthcare resources were defined as hospital admissions, therapeutic warm baths, physiotherapist visits, and outpatient physician visits. Healthcare resource utilization was evaluated using a questionnaire asking patients whether or not they had used the healthcare resource during the 48 weeks preceding enrollment in study 0881A3-402 (NCT00247962) and during the 48 weeks of treatment in this extension study (0881A3-405).
  • Number of Patients Taking Sick Leave in the 48 Weeks Before and During Treatment [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
    Patients were asked whether or not they had taken sick leave during the 48 weeks preceding enrollment in study 0881A3-402 (NCT00247962) and during the 48 weeks of treatment in this extension study (0881A3-405).
Health Economics Outcomes: assessment of quality of life and health care resource utilization and work status
Complete list of historical versions of study NCT00410046 on ClinicalTrials.gov Archive Site
  • Number of Patients Utilizing Healthcare Resources During 48 Weeks of Treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Healthcare resources were defined as hospital admissions, therapeutic warm baths, physiotherapist visits, and outpatient physician visits. Healthcare resource utilization was evaluated using a questionnaire asking patients whether or not they had used the healthcare resource during the 48 weeks of treatment.
  • Number of Times Healthcare Resources Were Used Per Patient During 48 Weeks of Treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Healthcare resources were defined as hospital admissions, therapeutic warm baths, physiotherapist visits, and outpatient physician visits. Healthcare resource utilization was evaluated using a questionnaire asking all patients whether or not they had used the healthcare resource during the 48 weeks of treatment, and if so, how many times the resource was used. The mean number of times is based on those patients who responded to the questionnaire stating they had utilized healthcare resources (see outcome measure 3).
  • Number of Patients With Sick Leave During 48 Weeks Treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    The impact of treatment on work productivity was assessed by sick leave. Patients were asked whether or not they had taken sick leave during the 48 weeks of treatment, and if so, how many days.
  • Number of Sick Days Per Patient During the 48 Weeks of Treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Patients were asked whether or not they had taken sick leave during the 48 weeks of treatment, and if so, how many days. The mean number of days is based on those patients who had sick leave during the treatment period.
  • Change in Patient Global Assessment of Disease Activity From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    Patient Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity. The 0881A3-402 (NCT00247962) baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change in Total Back Pain Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    Total Back Pain was measured on a 0 to 100 mm VAS, with 0 mm indicating no pain. The 0881A3-402 (NCT00247962) baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change in Bath Ankylosing Spondylitis Functional Index (BASFI) Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    BASFI is a validated self assessment tool that determines the degree of functional limitation in Ankylosing Spodylitis (AS) patients. Utilizing a VAS of 0-10 (0=easy, 10=impossible), patients answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions, with a maximum score of 100 mm. The 0881A3-402 (NCT00247962) baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    BASDAI is a validated self assessment tool used to determine disease activity in patients with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) patient's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10. The 0881A3-402 (NCT00247962) baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change in Bath Ankylosing Spondylitis Metrology Index (BASMI) Score From Baseline to Weeks 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. Each measure was scored 0-2 (0=normal mobility, 2=severe reduction) to give a final score ranging 0 to 10. The 0881A3-402 (NCT00247962) baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score for Fatigue From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    BASDAI is a validated self assessment tool used to determine disease activity in patients with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) patient's answered 6 questions measuring discomfort, pain and fatigue. The fatigue-specific score is presented here. The 0881A3-402 (NCT00247962) baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change in Baseline Ankylosing Spondylitis Quality of Life (ASQoL) Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    ASQoL is a questionnaire that assesses disease-specific quality of life (QoL). It consists of 18 statements that are relevant to the physical and mental conditions for a patient with Ankylosing Spondylitis (AS): mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each statement is answered by the patient as a 'Yes' (scored as 1) or 'No' (scored as 0). All item scores are summed to give a total score. Total score can range from 0 (good QoL) to 18 (poor QoL). The 0881A3-402 baseline score was used as the baseline for this analysis. Change = baseline - week 38.
  • Change From Baseline Haywood Quality of Life Score From Baseline to Week 38 [ Time Frame: Baseline and 38 weeks ] [ Designated as safety issue: No ]
    Haywood quality of life instrument was utilized in the United Kingdom as the ASQoL measure. The ASQoL is an AS-specific measure of QoL, scores range from 0 (good QoL) to 80 (poor QoL). ASQoL is intended to measure the quality of life by means of questions about mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Patient's 0881A3-402 baseline score was used in the analysis. Change=baseline-week 38.
Not Provided
Not Provided
Not Provided
 
Extension Study Evaluating Etanercept in Ankylosing Spondylitis
An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis

The primary purpose of this study is to evaluate the health care resource utilization and work status of patients with ankylosing spondylitis undergoing treatment with etanercept by comparing study evaluations with the baseline evaluations in the ASCEND (0881A3-402)(NCT00247962) study.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ankylosing Spondylitis
Drug: Enbrel (etanercept)
Etanercept 50 mg SC injection once weekly
Other Name: Enbrel
Experimental: Etanercept (ETN)
Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
Intervention: Drug: Enbrel (etanercept)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Patients who completed 16 weeks of treatment and have completed the baseline health care resource utilization questionnaire at screening in the ASCEND study 0881A3-402-WW from participating countries.

Exclusion criteria:

  • Withdrawal from the ASCEND study for safety or any other reason.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom,   Denmark,   Finland,   Sweden
 
NCT00410046
0881A3-405
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth Reserach
Wyeth is now a wholly owned subsidiary of Pfizer
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP